Valuation : Immutep Limited

Market Cap 64.84M 46.5M 39.99M 37.73M 34.38M 64.26M 4.45B 449M 173M 2.26B 175M 171M 7.16B P/E 2027 *
-2.2x
P/E 2028 * -3.26x
Enterprise Value 29.44M 21.11M 18.16M 17.13M 15.61M 29.17M 2.02B 204M 78.52M 1.02B 79.28M 77.54M 3.25B EV / Sales 2027 *
14.4x
EV / Sales 2028 * -0.72x
Free-Float
96.98%
Yield 2027 *
-
Yield 2028 * -
1 day+29.55%
1 week+18.75%
Current month+18.75%
1 month+14.00%
3 months+21.28%
6 months+26.67%
Current year-86.27%
1 week 0.04
Extreme 0.042
0.06
1 month 0.04
Extreme 0.042
0.06
Current year 0.03
Extreme 0.028
0.47
1 year 0.03
Extreme 0.028
0.47
3 years 0.03
Extreme 0.028
0.48
5 years 0.03
Extreme 0.028
0.71
10 years 0.03
Extreme 0.028
0.72
Manager TitleAgeSince
Chief Executive Officer 53 09/07/2014
Director of Finance/CFO - 01/03/2018
Chief Tech/Sci/R&D Officer - 01/07/2025
Director TitleAgeSince
Director/Board Member 53 09/07/2014
Chairman 76 17/11/2017
Director/Board Member 57 12/02/2014
Date Insider Type Main position Quantity % Market Cap. Importance
3/18/26 A Other

Chief Technology Officer

14,224,374 0.9652%
3/18/26 A Other

Executive/Senior Manager

5,174,048 0.3511%
3/18/26 A Other

Chief Executive Officer

18,477,395 1.2538%
Change 5-day change 1-year change 3-year change Capi.($)
+27.27%+18.75%-76.25%-80.34% 46.5M
-0.56%-8.08%-3.88%+10.58% 46.05B
-2.08%-3.57%+402.72%+533.09% 43.59B
+0.12%-5.27%+39.94%+20.50% 42.35B
-2.62%-5.76%+8.88%+77.44% 38.86B
-1.26%-3.37%+11.87%+40.55% 32.24B
+0.16%-3.65% - - 17.16B
-0.54%-1.72%+22.34%+115.10% 16.28B
-0.03%-3.46%+12.68%+30.90% 14.32B
-1.92%-6.94%+78.12%+36.68% 13.03B
Average +2.08%-4.87%+55.16%+87.17% 26.39B
Weighted average by Cap. -1.08%-5.04%+86.53%+128.45%

Financials

2027 *2028 *
Net sales 2.05M 1.47M 1.26M 1.19M 1.09M 2.03M 141M 14.21M 5.47M 71.29M 5.52M 5.4M 226M 1.55M 1.11M 956K 902K 822K 1.54M 106M 10.74M 4.13M 53.91M 4.17M 4.08M 171M
Net income -26.6M -19.07M -16.4M -15.48M -14.1M -26.36M -1.82B -184M -70.94M -925M -71.62M -70.06M -2.94B -32.25M -23.13M -19.89M -18.77M -17.1M -31.96M -2.21B -224M -86.03M -1.12B -86.86M -84.96M -3.56B
Net Debt -35.41M -25.39M -21.84M -20.6M -18.77M -35.09M -2.43B -245M -94.44M -1.23B -95.35M -93.27M -3.91B -65.95M -47.3M -40.68M -38.38M -34.96M -65.36M -4.52B -457M -176M -2.29B -178M -174M -7.29B
Logo Immutep Limited
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Employees
31
Date Price Change Volume
11/09/26 A$0.0560 +27.27% 41,669,231
10/09/26 A$0.0440 -4.35% 12,826,028
09/09/26 A$0.0460 -2.13% 8,083,492
08/09/26 A$0.0470 +2.17% 5,376,462
07/09/26 A$0.0460 -4.17% 4,456,966
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
0.0440AUD
Average target price
0.1033AUD
Spread / Average Target
+134.84%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!